Avita Medical

AVITA Medical, Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's skin to use in the treatment of acute thermal burns in patients eighteen years and older. AVITA Medical, Inc. has a research agreement with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. was incorporated in 2000 and is based in Valencia, California.

Our mission is to develop and deliver innovative, high quality medical devices for the treatment of wounds and other skin conditions.

Our vision is to develop the world's leading treatments for skin and soft-tissue conditions with minimal pain, minimal cost and minimal downtime, so more people can enjoy healthier, more vibrant lives.

Avita Medical has been recognized with numerous awards and accolades, including the Medical Design Excellence Award, the Frost & Sullivan New Product Technology Award, and the HealthTech Innovation Showcase Award.